Regulatory approval risk
Products must clear country-specific approval and compliance requirements before sale.
- Scope
- U.S., EMEA, APAC
- Materiality
- high
ChronoScale Holdings Corp
ChronoScale Holdings Corp is a U.S.-based medical robotics company focused on wearable robotic exoskeletons for rehabilitation and mobility support. Its business centers on the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal device families, along with related services such as warranty coverage, repairs, and training.
31,9 %
−23,9 %
−70,3 %
−15,1 %
0.51
0.46
| % | |
|---|---|
| Enterprise Health devices | 55% Robotic exoskeletons sold or subscribed for clinical rehabilitation use in healthcare facilities. |
| Personal Health devices | 20% Wearable exoskeletons used by individuals for personal mobility and rehabilitation support. |
| Subscriptions and financing arrangements | 10% Device access arrangements sold through finance partners or subscription structures. |
| Service and maintenance | 10% Fee-based repair, maintenance, and loaner-device services for installed products. |
| Training and support | 5% Online and in-person training, clinical support, and portal-based device services. |
The company sells primarily to healthcare providers and distributors that serve rehabilitation and mobility markets...
- Enterprise Health providersprimary
Hospitals, IRFs, LTACHs, SNFs, and outpatient clinics buy EksoNR and Ekso Indego Therapy for rehabilitation programs.
- Integrated delivery networksprimary
Large provider networks buy multi-unit systems to standardize rehabilitation workflows and improve purchasing economics.
- Distributorsprimary
Independent distributors buy and resell products in parts of EMEA and APAC, especially outside direct-sales markets.
- Personal Health userssecondary
Individuals and their care channels buy Ekso Indego Personal for mobility and rehabilitation support.
- Finance partnerssecondary
Third-party financing partners purchase devices in subscription structures and contract with end customers.
The company sells across the Americas, EMEA, and APAC, with direct sales in the Americas and a mix of direct and...
- •Americas are served mainly through a direct salesforce
- •EMEA uses direct sales in German-speaking countries
- •Non-German Europe relies heavily on distributors
- •APAC is a mix of direct and indirect channels
- •Foreign approvals and certification vary by country
- •Distributor coverage affects access and revenue growth
The company is focused on expanding adoption of its rehabilitation and personal mobility products through clinical...
01
Expand reimbursement and coverageshort-term
Coverage determines affordability and adoption for Personal Health devices.
02
Increase clinical adoptionshort-term
Enterprise Health sales depend on evidence, stakeholder education, and workflow fit.
03
Broaden product portfoliomedium-term
New devices can extend the addressable market and support future growth.
04
Preserve strategic flexibilityshort-term
A strategic transaction could reshape the business or unlock value.
The business depends on regulatory approvals, reimbursement coverage, and adoption of a relatively early-stage...
Distributor concentration
Independent distributors are principal customers in several non-direct markets.
- Scope
- Non-German Europe and parts of APAC
- Materiality
- high
Reimbursement and coverage risk
Personal Health growth depends on insurance coverage and reimbursement processes.
- Scope
- Personal Health
- Materiality
- high
Technology and competition risk
Exoskeleton technology remains early-stage and competitors are developing alternatives.
- Scope
- Medical robotics market
- Materiality
- medium
Cybersecurity risk
The company processes sensitive data and relies on connected systems and vendors.
- Scope
- Operations and customer data
- Materiality
- medium
Revenue recognition and SSP allocation
Affects timing and mix of reported revenue
Warranty and future service costs
Affects gross margin and accrued liabilities
Fair value of warrants and preferred stock
Affects other income/expense and equity
Inventory valuation
Affects gross profit and working capital
Deferred tax asset recoverability
Affects tax assets and net income
Lease accounting
Affects leverage and operating costs
: 17.7.2026